 |
 |
 |
 |
 |
This survey is intended only for flow cytometry laboratories
analyzing specimens which are billed to patients or insurance
companies. Please do not return this form if you are a research
facility. Results of this survey will be presented at the CAC
meeting in Charleston, SC in August. There are 40 questions and the
survey should take 15-20 mins. to complete. Thank you for your
help!
Please return form to:
Dr. Philip McCoy, The Flow Cytometry Lab
e-mail: pmccoy@umdnj.edu
Dept. of Pediatrics, Three Cooper Plaza, Suite 410
Camden, NJ 08103
or FAX to (609) 338-1468
Check here if lab is in the U.S.A.____
1. Site of Lab (check one): Hospital-based ____ Reference___
Other(specify) __________________________
2. Type of Lab: Flow Cytometry only ___ Flow Cytometry & Image ___
Flow Cytometry & Hematology ___Flow Cytometry & Immunology___
Other (specify)____________________________
3. Departmental Affiliation:
Pathology___ Medicine___ Pediatrics___
Surgery___ Other (specify)___
4. The Lab is inspected by: CAP___ JCAHO___ CLIA___ Other
(specify)_____________________________________
5. What percent of the flow cytometry specimens in your facility
is from HMOs or other managed health care plans? _____%
6. How many flow cytometers are in your facility? _______
7. How many image cytometers are in your facility? _______
PERSONNEL
8. Number of full time employees (FTEs) who devote primary effort
to flow cytometry. ______
9. Education of Lab Director. PhD__ MD___ DO___ DDS___ MS___
BS___ Other (specify)__________________
10. Education of Lab Supervisor. PhD___ MD___ DO___ DDS___ MS___
BS___ Other (specify)______________________
11. Are same individuals trained for sample preparation &
analysis?. Yes___ No___
12. Are operators MT (ASCP) with cytometry certificate?
Yes___ No___
13. In the last 2 years, are FTE's for Flow cytometry increasing
or decreasing?
Increasing___ Decreasing___ Unchanged___
SPECIMENS & TESTS
14. Total number of specimens analyzed in 1994._______
15. Test performed (check all that apply):
a) Leukemia/lymphoma immunophenotyping___ b) CD4 counts___
c) DNA/cell cycle analysis___ d) reticulocyte counts___
e) mitogen stimulation___ f) oxidative burst___
g) phagocytosis___
h) Lymphocyte immunophenotyping (other than AIDS/HIV)____
i) Other (specify)_________________________________
16. Which test from question 15 is most often performed?________
17. Immunophenotyping performed on clinical specimens (check all
that apply): 1 color___ 2 color___ 3 color___4 color___
5 color___
18. Has the number of specimens for FCM increased or decreased
in the past 2 yrs? Increased___ Decreased___ Unchanged___
19. Are you evaluating other methods for some of these tests to
replace current flow cytometric assays? Yes___ No___
If yes, please give examples:__________________________
20. How many markers are analyzed in your average leukemia
immunophenotyping?____________
21. Do you have separate marker panels for lymphoid and myeloid
leukemias? Yes___ No___
22. Do you ever run both marker panels on one specimen?
Yes___ No___
23. Do you "customize" marker panels for each specimen?
Yes___ No ___
INTERPRETATION AND REPORTING
24. Written interpretations are written for:
Leukemia/Lymphoma immunophenotyping___ CD4 counts___
DNA/cell cycle___ reticulocyte count___
mitogen stimulation___ O2 burst___phagocytosis___
Other (specify)_______________________
25. The interpretive reports are written by: Lab Director___
Lab Supervisor___ Pathologist___ Hematologist___
Other (specify_________________________
26. Are FCM interpretive reports separate from other pathology
reports or are they integrated into one comprehensive
pathology report?
Separate____ Comprehensive___ Other (specify) ___
27. Does the Flow Cytometry lab provide morphologic analysis?
Yes___ No___
28. Does the Flow Cytometry lab provide cytochemical stains?
Yes___ No___
if yes, are these performed prior to flow cytometry? Yes__ No__
29. What do you feel is the most important prognostic
information for leukemia?
lineage___ ploidy___ cell cycle___
aberrant marker expression___ MDR___ other (specify)__________
30. What do your clinicians feel is the most important
prognostic information for leukemia?
lineage___ ploidy___ cell cycle___
aberrant marker expression___ MDR___ other (specify)__________
31. Do you report intensity of marker staining? Yes ___ No____
Why or why not (how is it used)?____________________________
32. Do you use CD45 for gating leukemias? Yes___ No___
33. Do you have in-house reference ranges for:
YES NO
Adult Peripheral Blood ___ ___
Pediatric Peripheral Blood ___ ___
Adult Bone Marrow ___ ___
Pediatric Bone Marrow ___ ___
Adult Lymph Node ___ ___
Pediatric Lymph Node ___ ___
Other (specify)____________ ___ ___
DNA/CELL CYCLE ANALYSIS
34. What specimens do you perform DNA/Cell Cycle studies on?
Leukemias___ lymphomas___ breast tumors___
prostate tumors___ ovarian tumors___
stomach/colon tumors___ lung tumors___
squamous cell carcinomas___ melanomas___
others (specify)
35. For cell cycling, do you report S phase separate from G2M?
Yes___ No___
36. How do you define slow proliferation? (give %)
___% S or ___% S+G2M
37. Are ploidy and/or proliferation studies included in the
histology/pathology report or is the flow cytometry data
reported separately?
part of histology report___ separate___
38. Software used for DNA/cell cycle analysis (check all that
apply):
Cellfit____ Modfit____ ModfitLT____ Cytologic____
Multicycle____ Multiplus____ LYSYSII____ FCAP-1 ____
Cicero ____ Other (specify) _______________________
CHARGES
39. How much do you charge for the technical component of flow
cytometric analyses?
CHARGE
Immunophenotyping (per marker) ______
DNA/ cell cycle analysis _____
Mitogen stimulation _____
Oxidative burst _____
Reticulocyte count _____
Other (specify) _____
40. How much do you charge for the interpretive (professional)
component of flow cytometric analyses?
CHARGE
Immunophenotyping (per marker) _____
DNA/ cell cycle analysis _____
Mitogen stimulation _____
Oxidative burst _____
Reticulocyte count _____
Other (specify) _____
USE THE SPACE BELOW FOR ANY ADDITIONAL COMMENTS OR OBSERVATIONS
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web